Biotimize

Contract Development & Manufacturing Organization

Biotimize CDMO Graphics
De-risking your journey to clinical manufacturing

Global Vision & End-to-End Bioprocess Execution

Biotimize operates with a long-term global vision and a Phase-Appropriate regulatory architecture embedded from day zero. We empower biotechs and global biopharma leaders with custom bioprocess design, structured technology transfer, and scalable manufacturing pathways supporting a predictable transition fro discovery to clinical readiness.

End-to-End Continuity

Complete Life-Cycle Support: Transfer or Scale with Us

We design bioprocesses that are built to travel or built to grow. Whether your strategic roadmap calls for technology transfer to an international partner or long-term manufacturing within our expanding facility, Biotimize provides end-to-end operational continuity.

Option A: Phase-Appropriate Tech Transfer

Should your commercial strategy require manufacturing at a global CMO partner, we deliver a fully documented, phase-appropriate Tech Transfer package (ICH Q8-Q11 compliant) ensuring smooth, frictionless onboarding at target sites worldwide.

Option B: Scalable In-House Expansion

Grow your pipeline directly with Biotimize. Our modular facility design allows seamless capacity scaling alongside your clinical trajectory—providing reliable, ongoing supply from early-stage trials through initial commercial launch.

Manufacturing Game Plan

Building the Future of Flexible Biomanufacturing

Status: Basic Engineering Design Phase
100% Single-Use (SU)

Fully single-use infrastructure ensuring maximum operational flexibility, rapid product changeover, and minimum risk of cross-contamination.

Up to 200L Scale

Initial operational bioreactor capacities up to 200L—ideal for high-value therapeutics, advanced therapies, recombinant proteins, and clinical supply.

Tech Transfer & Scale-Up

Seamless scale-up execution transferring benchtop processes into robust pilot and clinical-scale bioreactors with validated comparability metrics.

Global Regulatory Architecture

Designed for Stringent Global Compliance

Our facility layout, cleanroom architecture, and quality management systems are engineered from the ground up to comply with the world's most rigorous regulatory authorities:

ANVISA (Brazil)
FDA (United States)
EMA (Europe)
PMDA (Japan)
MFDS (South Korea)
TGA (Australia)
Quality Standards

Strict adherence to ICH Guidelines (Q8 Pharmaceutical Development, Q9 Quality Risk Management, Q10 Pharmaceutical Quality System, and Q11 Development & Manufacture) to support robust regulatory documentation across international markets.

For Biopharma & Biotechs

Secure Priority Capacity

Partner with Biotimize early to lock in custom bioprocess design, early tech transfer slots, and Capacity Reservation for upcoming clinical and pilot supply runs.

Reserve Capacity
For Investors & Partners

Join Our Growth Journey

We are currently raising capital to accelerate facility development and expand Biotimize's CDMO manufacturing capabilities.

Access Investor Deck

Let’s Build the Next Generation of Biomanufacturing Together

Whether you are looking for a trusted CDMO partner for end-to-end tech transfer or seeking to participate in our capital raise, our executive team is ready to connect.

Schedule Executive Consultation

LGPD

Rigorous company in relation to the general data protection law (LGPD)

Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:

What are the data types? Personal data:
“Information relating to an identified or identifiable natural person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.

Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.

What data does our Company collect? Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.

Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.

How do they use my data? The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.

Have you got any questions? Talk to the Data Protection Manager (DPO) by email: dpo@biotimize.com.br
You will be able to clarify doubts related to the processing of personal data.